Compare YDDL & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YDDL | IPSC |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | Philippines | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 358.9M | 370.2M |
| IPO Year | N/A | 2021 |
| Metric | YDDL | IPSC |
|---|---|---|
| Price | $15.34 | $2.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 304.7K | ★ 1.4M |
| Earning Date | 05-25-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $109,164,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $40.85 | ★ N/A |
| Revenue Growth | N/A | ★ 1556.76 |
| 52 Week Low | $3.61 | $0.34 |
| 52 Week High | $15.90 | $2.97 |
| Indicator | YDDL | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 71.60 | 49.37 |
| Support Level | $4.77 | $1.87 |
| Resistance Level | $15.90 | $2.68 |
| Average True Range (ATR) | 1.94 | 0.22 |
| MACD | 0.35 | -0.03 |
| Stochastic Oscillator | 89.67 | 38.97 |
One and one Green Technologies Inc is engaged in recycling, production, and trading of recycled scrap metals in the Republic of Philippines. The company process raw materials and generate final products that include copper alloy ingot, aluminum scrapes, plastic beads, and others. It provides economical and flexible solutions to the challenges of electronic waste, metal scrap and industrial recycling. By providing lower-cost alternatives for processing recycled materials, It is not only Contributing to environmental sustainability but also highlight its role as a modern and specialized recycling company.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.